Literature DB >> 12892708

Getting oncolytic virus therapies off the ground.

John C Bell1, Brian Lichty, David Stojdl.   

Abstract

An international meeting was held on the development and application of replicating viruses for cancer therapy this past March in Banff, Alberta. In this review, using the presentations at this meeting as a backdrop, we discuss how recent scientific and clinical findings are reshaping the development of oncolytic virus therapeutics. Here we identify some of the obstacles that these therapeutics face and discuss evolving strategies, both preclinically and clinically, that are facilitating oncolytic virus development.

Entities:  

Mesh：

Year:  2003        PMID： 12892708     DOI： 10.1016/s1535-6108(03)00170-3

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  38 in total

1.  Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.

Authors:  M Ahmed; S Puckett; D S Lyles
Journal:  Cancer Gene Ther       Date:  2010-08-20       Impact factor: 5.987

2.  Use of oncolytic viruses for the eradication of drug-resistant cancer cells.

Authors:  Dominik Wodarz
Journal:  J R Soc Interface       Date:  2009-02-06       Impact factor: 4.118

3.  Proteomic analyses of gastric cancer cells treated with vesicular stomatitis virus matrix protein.

Authors:  Dequan Zeng; Tao Zhang; Shengtao Zhou; Hao Hu; Jingyi Li; Kai Huang; Yunlong Lei; Kui Wang; Yong Zhao; Rui Liu; Qiu Li; Yanjun Wen; Canhua Huang
Journal:  Protein J       Date:  2011-06       Impact factor: 2.371

4.  Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx.

Authors:  Daniel F Gaddy; Douglas S Lyles
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

5.  Targeting tumor vasculature with an oncolytic virus.

Authors:  Caroline J Breitbach; Naomi S De Silva; Theresa J Falls; Usaf Aladl; Laura Evgin; Jennifer Paterson; Yang Yang Sun; Dominic G Roy; Julia L Rintoul; Manijeh Daneshmand; Kelley Parato; Marianne M Stanford; Brian D Lichty; Aaron Fenster; David Kirn; Harold Atkins; John C Bell
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

6.  A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon.

Authors:  Maria D Gainey; Mary J Manuse; Griffith D Parks
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

7.  ODE models for oncolytic virus dynamics.

Authors:  Natalia L Komarova; Dominik Wodarz
Journal:  J Theor Biol       Date:  2010-01-18       Impact factor: 2.691

8.  Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.

Authors:  Yushui Wu; Xueqing Lun; Hongyuan Zhou; Limei Wang; Beichen Sun; John C Bell; John W Barrett; Grant McFadden; Jaclyn A Biegel; Donna L Senger; Peter A Forsyth
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

9.  Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Authors:  Feorillo Galivo; Rosa Maria Diaz; Uma Thanarajasingam; Dragan Jevremovic; Phonphimon Wongthida; Jill Thompson; Timothy Kottke; Glen N Barber; Alan Melcher; Richard G Vile
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

10.  Towards predictive computational models of oncolytic virus therapy: basis for experimental validation and model selection.

Authors:  Dominik Wodarz; Natalia Komarova
Journal:  PLoS One       Date:  2009-01-30       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.